- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03184948
Understanding Neonatal Jaundice in Rwanda
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Kigali, Rwanda
- University Central Hospital of Kigali
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- For patient level record (de-identified), diagnosed by the facility for having infant jaundice
- The facilities are included based on selection by the Ministry of Health for receiving additional phototherapy machines.
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Phase 1
This is the first set of randomly selected hospitals to receive the intervention (Brilliance device). The intervention to be provided is the phototherapy device, Brilliance. *No individual participants are recruited for this study. |
The intervention is the provision of the Brilliance phototherapy machines to hospitals.
This device is to be provided to facilities regardless of the study -- the study's involvement has been to collaborate with the Ministry of Health so that Brilliance is distributed in a randomized staggered method.
In that sense, the study may be considered observational, as the study is not driving whether or not a hospital receives Brilliance, only when it receives Brilliance in a short time frame.
|
ACTIVE_COMPARATOR: Phase 2
This is the second set of hospitals to receive the device. For the first three months, they receive no intervention, after which they become part of the "active comparator" arm. The intervention to be provided is the phototherapy device, Brilliance. *No individual participants are recruited for this study. |
The intervention is the provision of the Brilliance phototherapy machines to hospitals.
This device is to be provided to facilities regardless of the study -- the study's involvement has been to collaborate with the Ministry of Health so that Brilliance is distributed in a randomized staggered method.
In that sense, the study may be considered observational, as the study is not driving whether or not a hospital receives Brilliance, only when it receives Brilliance in a short time frame.
|
NO_INTERVENTION: Phase 3
This is the last set of hospitals to receive the device. For the first six months, they receive no intervention, after which the study is completed and they are given the device Brilliance. *No individual participants are recruited for this study. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Length of treatment for infant jaundice
Time Frame: Through study completion, an average of 9 months
|
Number of hours infant diagnosed with jaundice is provided phototherapy (PT).
This is calculated by subtracting the age at which the patient is first given PT from the age at which the patient is removed from PT.
The analysis is conditional on the subset of infants diagnosed with jaundice.
|
Through study completion, an average of 9 months
|
Length of hospital duration for infant jaundice
Time Frame: Through study completion, an average of 9 months
|
This is measured by the duration of stay at the facility, as measured by the time between being admitted and being discharged.
The analysis is conditional on the subset of infants diagnosed with jaundice.
|
Through study completion, an average of 9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Increased rate of reduction in bilirubin
Time Frame: Through study completion, an average of 9 months
|
Using different measures of estimated bilirubin levels for one patient and the age at which those tests were provided, we will estimate the change in bilirubin levels over the change in age (by hours) as the rate of reduction in bilirubin levels.
This assumes that age at diagnosis is similar across treatment arms.
If this is not the case or if our estimates are not precise, we will use maximum bilirubin levels recorded as a proxy.
The analysis is conditional on the subset of infants diagnosed with jaundice.
|
Through study completion, an average of 9 months
|
Improved Treatment of Jaundice
Time Frame: Through study completion, an average of 9 months
|
An indicator variable for whether the patient was treated at the facility (as opposed to being referred elsewhere for treatment).
|
Through study completion, an average of 9 months
|
Improved Treatment of Jaundice By Not Being Referred Elsewhere
Time Frame: Through study completion, an average of 9 months
|
An indicator variable for whether the patient was treated at the facility (as opposed to being referred elsewhere for treatment).
|
Through study completion, an average of 9 months
|
Improved Treatment of Jaundice by Receiving Phototherapy
Time Frame: Through study completion, an average of 9 months
|
An indicator variable for whether the patient received phototherapy.
|
Through study completion, an average of 9 months
|
Improved Treatment of Jaundice by Not Sharing Phototherapy
Time Frame: Through study completion, an average of 9 months
|
An indicator variable for whether the patient did not share a phototherapy machine with another infant
|
Through study completion, an average of 9 months
|
Improved Treatment of Jaundice by Using Single Phototherapy Device
Time Frame: Through study completion, an average of 9 months
|
An indicator variable for whether the patient used multiple phototherapy machines;
|
Through study completion, an average of 9 months
|
Improved Treatment of Jaundice by Reducing Exchange Transfusions
Time Frame: Through study completion, an average of 9 months
|
An indicator variable for whether the patient received an exchange transfusion
|
Through study completion, an average of 9 months
|
Improved Treatment of Jaundice by Not Meeting Threshold for Exchange Transfusion
Time Frame: Through study completion, an average of 9 months
|
An indicator variable for whether the patient reached the threshold for exchange transfusion
|
Through study completion, an average of 9 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Age at time of jaundice diagnosis
Time Frame: Through study completion, an average of 9 months
|
Average age of infant at the time of jaundice diagnosis
|
Through study completion, an average of 9 months
|
Jaundice diagnosis rates
Time Frame: Through study completion, an average of 9 months
|
Rate of infant jaundice diagnoses per month per admitted infants as reported by hospital facility
|
Through study completion, an average of 9 months
|
Jaundice diagnosis levels
Time Frame: Through study completion, an average of 9 months
|
Number of infant jaundice diagnoses per month as reported by the hospital facility
|
Through study completion, an average of 9 months
|
Fee Charged
Time Frame: Through study completion, an average of 9 months
|
Reduction in cost of jaundice case (fee charged and amount earned by facility per diagnosed jaundice patient) as reported by hospital facility.
|
Through study completion, an average of 9 months
|
Increased technical capacity by Number of Phototherapy Devices
Time Frame: Through study completion, an average of 9 months
|
Number of Phototherapy machines at facility
|
Through study completion, an average of 9 months
|
Increased technical capacity by Number of Operational Phototherapy Devices
Time Frame: Through study completion, an average of 9 months
|
Number of operational phototherapy machines at facility
|
Through study completion, an average of 9 months
|
Increased technical capacity by Improved Irradiance Levels
Time Frame: Through study completion, an average of 9 months
|
Average irradiance levels of phototherapy machines at the hospital facility
|
Through study completion, an average of 9 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ketki Sheth, PhD, University of California, Merced
- Principal Investigator: Lisine Tuysenge, MD, Rwanda Pediatric Association
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FWA Assurance No: 00001973
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Study Data/Documents
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Jaundice, Neonatal
-
Muhammad ZarkNot yet recruitingPhysiological Neonatal Jaundice | Physiological HyperbilirubinaemiaPakistan
-
Ege UniversityAssociate Professor Figen YARDIMCINot yet recruitingUnspecified Fetal and Neonatal Jaundice
-
University of AarhusCompletedUncomplicated Neonatal HyperbilirubinemiaDenmark
-
Guangzhou Women and Children's Medical CenterRecruitingNeonatal Hyperbilirubinemia | Neonatal Jaundice | Hemolysis NeonatalChina
-
Guizhou Provincial People's HospitalRecruiting
-
University Hospital, LilleInstitut National de la Santé Et de la Recherche Médicale, FranceRecruitingNeonatal JaundiceFrance
-
Picterus ASNorwegian University of Science and TechnologyTerminatedNeonatal JaundiceUganda
-
University of MinnesotaHennepin Healthcare Research InstituteCompleted
-
National Liver Institute, EgyptCompleted
-
Picterus ASIntermountain Medical CenterRecruitingNeonatal JaundiceUnited States
Clinical Trials on Brilliance
-
MediBeaconCompletedAcute Kidney InjuryUnited States
-
Carmel Medical CenterEuropean Foundation for the Study of DiabetesUnknown
-
Washington University School of MedicineNational Cancer Institute (NCI)TerminatedHead and Neck Cancer | Lung Cancer | Brain CancerUnited States
-
University of AarhusDanish Heart Foundation; Danish Research Agency; Philips Medical SystemsCompletedAtherosclerosisDenmark
-
MediBeaconCompleted